Sentences with phrase «of oncology with»

It was led by Dr. Tim Whelan, professor of oncology with McMaster University's Michael G. DeGroote School of Medicine and a radiation oncologist at Hamilton Health Sciences Juravinski Cancer Centre.

Not exact matches

Jim Cramer sits down with the executive chairman of oncology giant Novocure to get the latest on its cutting - edge tumor therapy.

BIG DATA AND CANCER: STANDARDIZATION With Mary Beckerle of the University of Utah; Clifford A. Hudis of the American Society of Clinical Oncology; Greg Simon of The White House; and Clifton Leaf of Fortune — Report by Erika Fry — Video: The Crucial Data That Will Help You Fight Cancer — Video of the entire session

Announced a worldwide collaboration with Sangamo Therapeutics, Inc. (Sangamo) using Sangamo's zinc finger nuclease technology platform for the development of next - generation ex vivo cell therapies in oncology.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

Julia has also mapped competitive landscapes with a focus on immuno - oncology and melanoma as a member of the Oncology Team within the TechAtlas division of RA oncology and melanoma as a member of the Oncology Team within the TechAtlas division of RA Oncology Team within the TechAtlas division of RA Capital.

The Harvard Business School Kraft Precision Medicine Accelerator is working with the MMRF and other cancer partners to harness the potential of master protocols in precision oncology.

«We are pleased to share this vision with the unique blend of crossover funds, pharmaceutical companies, and venture capital investors participating in our Series B, and look forward to advancing our position as the leading biotech with a dual focus on synthetic lethality and immuno - oncology.»

Triphase in - licenses clinically enabled oncology assets with high - value potential and develops them in a shared risk model to proof - of - concept, then out - licenses or sells the product to create value.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

The divestment of the cancer business may be a deterrent for Takeda, since oncology was one of the areas it had highlighted as driving the case for a Shire deal, along with gastrointestinal medicine and neuroscience.

Combine this with dozens of oncology and ant - inflammatory collaborations for potentially first - in - class therapies, and you have a recipe for double - digit annual sales growth for years to come.

On Monday morning, as he did every two weeks, he would walk into the basement of the oncology center at Duke and sit with a hundred people who stared into the nothingness, waiting hours for their turns.

Women dealing with serious health issues, such as cancer, will have the added benefit of having someone from an oncology, breast center unit as part of the birthing team of doctors.

Outside of this group, I am building the Little Lives Lending Library, a project to serve children and families that are admitted to our two local children's hospitals, with particular attention to the Infant / Toddler Continuing Care and Oncology units.

«Particularly her knowledge of the needs of those children she works with in pediatric Oncology and the families of those children.

As a matter of urgency, we need to train more healthcare professional (doctors, nurses, and pharmacist) in paediatric oncology, expand treatment access to at least three others centres (Tamale, Cape Coast and Volta regions); and equip these facilities with good Labourites to be able to detect both solid and blood cancers.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

Professor Josep Tabernero, a member of the scientific committee for the EORTC - NCI - AACR Symposium and head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheoncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to otheOncology, Barcelona, Spain, commented: «These are encouraging results, which show that galeterone has significant clinical activity in men with castration - resistant prostate cancer that fails to respond to other drugs.

That's how Charles Sawyers, a 2009 Lasker Award winner and chair of human oncology and pathogenesis at Memorial Sloan - Kettering Cancer Center in New York City, made the connection with Bristol Myers Squibb (BMS) that led to second - generation treatments for chronic myeloid leukemia (CML).

His interest in research grew while he did his medical degree at Stanford, so he enrolled in Stanford's research - residency program, which allowed him to do 2 years of traditional residency training with a 3rd - year research fellowship in hematology - oncology.

«We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors,» said Benjamin Greenbaum, PhD, the senior author, who is affiliated with the departments of Medicine, Hematology and Medical Oncology, Pathology, and Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Subha Madhavan, an oncology professor and director of the Innovation Center for Biomedical Informatics (ICBI) at Georgetown University Medical Center in Washington, D.C., was next to praise her experience with a PSM graduate, named Shruti Rao, who earned her degree in molecular biotechnology at George Washington University, also in the nation's capital.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

By taking a high - cost drug with a low - fat meal — instead of on an empty stomach, as prescribed — prostate cancer patients could decrease their daily dose, prevent digestive issues and cut costs by 75 percent, according to a new study in the March 28, 2018, issue of the Journal of Clinical Oncology (JCO).

«Finding the optimal conditions to avoid interfering with immune cells working to eradicate cancer while preventing graft rejection and GVHD is the holy grail of bone marrow transplant,» says Leo Luznik, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The study of 1,003 men was conducted at the NIH in Bethesda, Md., from 2007 - 2014, with Peter A. Pinto, MD, the head of the prostate cancer section of the urologic oncology branch, serving as the senior investigator.

«Estimating from various studies that looked at increasing BMI and endometrial cancer risk, a woman with a Body Mass Index (BMI) of 40 would have approximately eight times greater risk of endometrial cancer than someone with a BMI of 25,» said first author Kristy Ward, MD, the senior gynecologic oncology fellow in the Department of Reproductive Medicine at UC San Diego School of Medicine.

Due to the increasing interest in digital health care systems, she moved to Roche's oncology department, where her activities included formulating and implementing validated assays, coupled with digital solutions and key contributions to the Discovery Biomarker portfolio and to the development of software tools for data mining purposes.

The Michigan Oncology Sequencing Program (MI - ONCOSEQ) facilitates integrative sequencing analysis of tumors from patients with advanced cancers.

Professor Paolo Boffetta (MD), the Annals of Oncology associate editor for epidemiology and Director of the Institute of Translational Epidemiology at the Icahn School of Medicine at Mount Sinai in New York (USA), commented: «These results are extremely important in showing that reducing cancer mortality can be achieved: priority should be given to research in cancers with unfavourable trends, such as pancreatic cancer, and in reducing cancer mortality disparities, both between countries (Central / Eastern versus Western Europe), and within countries, for example, between socioeconomic groups.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

The shortened regimen, described online Sept. 29 in the Journal of Clinical Oncology, begins with intravenous busulfan and fludarabine, two chemotherapeutic drugs that wipe out a patient's immune system and prepare his or her body to receive donated marrow.

Roche has four biologic cancer immunotherapy molecules in clinical trials that could work in powerful combinations with each other or with current drugs, says William Pao, global head of oncology discovery in Basel.

«Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML,» says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research meeting.

Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;

Using genome data from more than 50,000 cancer cases and 60,000 controls through the GAME - ON (Genetic Associations and Mechanisms in Oncology) network, the team compared telomere lengths with the risk of developing breast, lung, colorectal, ovarian and prostate cancers, including subtypes.

The study was led by Dr. Alexandre Zlotta, Director of Uro - Oncology at Mount Sinai Hospital, and researcher with the Lunenfeld - Tanenbaum Research Institute, part of Sinai Health System in Toronto, Canada, and Dr. Paul Boutros, Principal Investigator, Informatics and Bio-computing, Ontario Institute for Cancer Research (OICR).

Young people with body mass indexes (BMIs) over 30 are more likely to experience aggressive malignancies, says author Nathan A. Berger, MD, Hanna - Payne Professor of Experimental Medicine; director of the Center for Science, Health and Society; member of the Case Comprehensive Cancer Center; and professor of medicine, biochemistry, oncology and genetics at Case Western Reserve University School of Medicine.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene therapy.

The study — the largest to date assessing the mental and emotional health of patients with cancer using a fully standardized, diagnostic face - to - face interview — is published in the October 6 issue of the Journal of Clinical Oncology.

«We began with stem cells taken from cord - blood, which have fewer acquired mutations and little, if any, epigenetic memory, which cells accumulate as time goes on,» says Zambidis, associate professor of oncology and pediatrics at the Johns Hopkins Institute for Cell Engineering and the Kimmel Cancer Center.